SAN FRANCISCO, Jan. 21, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $400.0 million. The offering is expected to close on or about January 26, 2021, subject to customary closing conditions.
Read MoreSAN FRANCISCO, Jan. 14, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the launch of a new project with Bristol Myers Squibb, Janssen Research & Development, LLC (Janssen), Novartis and Genentech, a member of the Roche Group, to develop a standardized panel for MRD detection in patients with AML to support clinical trial testing across multiple drug development programs. The companies are working together to standardize how MRD data is generated and assessed in clinical trials helping to better establish the clinical utility of MRD as a biomarker in AML.
Read MoreJason Myers and his team were honored at the CBSA awards banquet last week with the Deal of the Year Award, a well-deserved honor. See video linked in the title of this article and embedded within.
Read MoreDec. 14, 2020 - 6:55 - Two Blind Brothers founders Bradford and Bryan Manning explain the idea behind their ‘Shop Blind’ challenge, which gives 100 percent of profits to the Foundation Fighting Blindness.
Read MoreYou needn’t be a daredevil to go backcountry skiing—just willing to clomp up a hill. Around the U.S., several new spots are easing newcomers into a sport where utter seclusion is the whole point.
Read MoreBlack Bear Energy's Victoria Stulgis on Energy Storage deployment for LBA Realty's sustainability program as part of ULI's Fall Event Innovation Fireside Chat. Click the title to link to the video.
Read MoreLightDeck Diagnostics, a company formed earlier this year from the merger of startups mBio and Brava Diagnostics, has raised $11 million in funding for a new high-speed COVID-19 test, according to a statement.
Read MoreAcquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease (TED)
Company plans to use private placement financing proceeds of $91 million to advance multiple compounds through phase 2 proof of concept studies in TED and to expand its orphan disease pipeline
Read More